Benign course of residual inflammation at end of treatment of liver transplant recipients after sofosbuvir based therapy

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 14, Issue 3

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

World Journal of Hepatology

ISSN

1948-5182

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Observational Study

World J Hepatol. Mar 27, 2022; 14(3): 602-611
Published online Mar 27, 2022. doi: 10.4254/wjh.v14.i3.602

Full Size Figure Download Figure

Figure 1 Hepatitis C RNA during and after treatment.

Citation: Ismail B, Benrajab KM, Bejarano P, Ruiz P, Sears D, Tzakis A, Zervos XB. Benign course of residual inflammation at end of treatment of liver transplant recipients after sofosbuvir based therapy. World J Hepatol 2022; 14(3): 602-611
URL: https://www.wjgnet.com/1948-5182/full/v14/i3/602.htm
DOI: https://dx.doi.org/10.4254/wjh.v14.i3.602

Ismail B, Benrajab KM, Bejarano P, Ruiz P, Sears D, Tzakis A, Zervos XB. Benign course of residual inflammation at end of treatment of liver transplant recipients after sofosbuvir based therapy. World J Hepatol 2022; 14(3): 602-611 [PMID: 35582292 DOI: 10.4254/wjh.v14.i3.602]

All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.